Dr. Nathan A. Pennell
Claim this profileCleveland Clinic Foundation
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
16 reported clinical trials
25 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
RET positive
2Lung Cancer
Global LeaderStage IV
Stage III
RET positive
Affiliated Hospitals
Clinical Trials Nathan A. Pennell is currently running
BDTX-1535 + Temozolomide
for Glioblastoma and Lung Cancer
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma multiforme (GBM) expressing EGFR alterations (Phase 1 only). All patients will self administer BDTX-1535 monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently enrolling.
Recruiting1 award Phase 1 & 214 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Nathan A. Pennell
Clinical Trial Related2 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Nathan A. Pennell has experience with
- Pembrolizumab
- Docetaxel
- Pemetrexed Disodium
- Carboplatin
- Gemcitabine Hydrochloride
- Pemetrexed
Breakdown of trials Nathan A. Pennell has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nathan A. Pennell specialize in?
Nathan A. Pennell focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Nathan A. Pennell currently recruiting for clinical trials?
Yes, Nathan A. Pennell is currently recruiting for 10 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Nathan A. Pennell has studied deeply?
Yes, Nathan A. Pennell has studied treatments such as Pembrolizumab, Docetaxel, Pemetrexed Disodium.
What is the best way to schedule an appointment with Nathan A. Pennell?
Apply for one of the trials that Nathan A. Pennell is conducting.
What is the office address of Nathan A. Pennell?
The office of Nathan A. Pennell is located at: Cleveland Clinic Foundation, Cleveland, Ohio 44195 United States. This is the address for their practice at the Cleveland Clinic Foundation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.